FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085

Contract Categories: Intellectual Property - License Agreements
EX-10.5 2 d850483dex105.htm EX-10.5 EX-10.5

Exhibit 10.5

 

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085

This First Amendment to Exclusive License Agreement (this “Amendment”), dated as of November 4, 2005, is made by and among The Regents of the University of

California, a California corporation (“The Regents”), Medivation, Inc ., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc, a Delaware corporation and subsidiary of Medivation (“MPT”)

WHEREAS, The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as of August 12, 2005 (the “Exclusive License Agreement”);

WHEREAS, The Regents, Medivation and MPT wish to strengthen the patent protection of certain members of the family of compounds covered in UC Case Nos 2004-129 and 2005- 438 by the filing of a patent application to cover additional selected diaiylthiohydantoin compounds, which are disclosed in UC Case No, 2006-260 entitled “Selected Diarylthiohydantoin Compounds,” by Samedy Ouk, Michael E lung, Derek Welsbie and Charlie D Chen, employees of The Regents, and Charles I Sawyers, an employee of HHMI and a member of the faculty of the University of California, Los Angeles;

WHEREAS, Medivation as the parent corporation of MPT will benefit directly from the agreements made herein;

WHEREAS, the parties mutually intend to enter into this First Amendment to amend the terms of the Exclusive license Agreement, as specified below.

THEREFORE, the patties hereby agree as follows:

1

 

Paragraph 1,1 (“Regents’ Patent Rights”) is deleted and replaced with the following,

which is amended to include “UC Case No. 2006-260” in the parenthetical at the end of

the paragraph:

11 “Regents’ Patent Rights” means The Regents interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent applications (requested under Paragraph 7,3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely supported in the specification and entitled to the priority date of the parent application) based on the patent applications listed in Appendix A (UC Case Nos 2004-129, 2005-438 and 2006-260).


 

2

 

Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A

attached to this First Amendment, which is amended to include the patent application to be filed under UC Case No 2006-260.

3, Paragraph 2 1 is deleted and replaced with the following, which is amended to delete

“Licensee” and replace it with “MPT .” The effect of this Amendment is that MPT is the sole recipient of the license granted pursuant to Paragraph 2 1 Notwithstanding this amendment, it is expressly understood that all other references to “Licensee” in the Exclusive License Agreement, including without limitation in Article 18 thereof (Indemnification), shall refer to Medivation and MPT collectively,

2

 

1 Subject to the limitations set forth in this Agreement, including the licenses granted to the United States Government and those reserved by HHMI set forth in the recitals and in Paragraph 2 2 and the rights reserved by The Regents in Paragraph 2.3, The Regents hereby grants to MPT an exclusive license (the “License”) under Regents’ Patent Rights, in jurisdictions where Regents’ Patent Rights exist, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law,

4

 

Except for the amendments specifically referenced above, all other terms of the Exclusive

License Agreement shall remain unchanged and in full force and effect,

The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their

authorized officers on the dates written below:

MEDIVATION, INC

Bv /s/ C. Patrick Machado

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

By: /s/ Claire T. Wake, Ph.D.

Name C, Patrick Machado

Name Claire T Wake, Ph D

T itle Senior Vice President and CFO

Title Assistant Director, licensing

Date 4 Nov, 05 Date November 4, 2005 MEDIVATION PROSTATE THERAPEUTICS, INC. f By /s/ C. Patrick Machado Name C, Patrick Machado T itle Senior Vice President and CFO

Date 4 Nov. 05


 

APPENDIX A (First Amendment)

REGENTS* PATENT RIGHTS

lIC Case No. 2004-129

PCT Patent Application No,, US05/05529 “Methods and Materials for Assessing Prostate Cancer Iherapies and Compounds,” filed February 23, 2005, based on US Provisional Patent Application No, 60/547,101 filed February 24, 2004, The inventors are Michael E Jung, Samedy Ouk, Charlie D, Chen and Derek Welsbie, employees of The Regents, and Charles I Sawyer s, an employee of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents

UC Case No. 2005-438

US Provisional Patent Application No, 60/680,835 “Novel Androgen Receptor Inhibitors with Minimal Agonistic Activities,” fried May 11, 2005 The inventors are Michael E. Jung, Samedy Ouk, Charlie D Chen and Derek Welsbie, employees of The Regents, and Charles L Sawyer s, an employee of the Howar d Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents This application, together with the patent application pertaining to UC Case No 2004-129, cover the compounds identified as RD1 through RD138, inclusive, on Exhibit A attached her eto ,

UC Case No. 2006-260

US Provisional Patent Application to be filed on “Selected Diarylthiohydantoin Compounds” based on UC Case No 2006-260 The inventors are Michael E. Jung, Samedy Ouk, Charlie D, Chen and Derek Welsbie, employees of The Regents, and Charles L Sawyers, an employee of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents This application will cover only the following diaiylthiohydantoin compounds developed in the labor atory of Michael E Jung, the structures of which are set forth on Exhibit A attached hereto:

? RD139 through RD142

? RD145 through RD163

? RD168


 

EXHIBIT A To Appendix A

[begins on Page 5]

2

 

1

 


 

 

RD2

 

RD3

 

RD4

 

RD5

 

RD6

 

RD7

 

RD8


 

RD9

 

RD10

 

RD11

 

RD12

 

RD13

 

RD14

 

RD15

 

RD16

 

RD17


 

 

RD18

 

RD19

 

RD20

 

RD20

 

RD22

 

RD23

 

RD24

 

RD25

RD18

 

RD#

 

RD26

 

RD1

 

RD8


 

 

RD28

 

RD28

 

RD29

 

RD30

 

RD31

 

RD32

 

RD33

 

RD34

 

RD35


 

RD37

 

RD38

 

RD39

 

RD40

 

RD41

 

RD42

 

RD43

 

RD44

 

RD27

 

RD35

 

RD35


 

 

RD45

 

RD46

 

RD47

 

RD48

 

RD49

 

RD50

 

RD51

 

RD52


 

 

RD53

 

RD54

 

RD55

 

RD57

 

RD58

 

RD59

 

RD60


 

RD61

 

RD62

 

RD63

 

RD64

 

RD65

 

RD66

 

RD67

 

RD45

 

RD53

 

RD52

 

RD60

 

RD36

 

RD44


 

RD68

 

RD69

 

RD70

 

RD71

 

RD72

 

RD73

 

RD74

 

RD75

 

RD#

 

O

 

RD61

 

O

 

RD67

 

RD67


 

 

RD78

 

RD79

 

RD80

 

RD81

 

RD82

 

RD83

 

RD84


 

RD85

 

RD86

 

RD87

 

RD88

 

RD89

 

RD90

 

RD91

 

RD78

 

RD78

 

RD84

 

RD84

 

RD68

 

RD75


 

RD92

 

RD93

 

RD94

 

RD95

 

RD85

 

RD85

 

RD#

 

RD91


 

 

RD96

 

RD97

 

RD98

 

RD99

 

RD100

 

RD101


 

RD102

 

RD103

 

RD104

 

RD105

 

RD106

 

RD107

 

RD108

 

RD109

 

RD96

 

RD96

 

RD101

 

RD101

 

RD92


 

RD110

 

RD111

 

RD112

 

RD113

 

RD114

 

RD115

 

RD116

 

RD#

 

RD#

 

RD109

 

RD109


 

RD117

 

RD118

 

RD119

 

RD120

 

RD121

 

RD122

 

RD123

 

RD110

 

RD110

 

RD#

 

RD#


 

 

RD124

 

RD125

 

RD126

 

RD127

 

RD128

 

RD129

 

RD130

 

RD131

 

RD132


 

RD133

 

RD134

 

RD135

 

RD136

 

RD137

 

RD138

 

RD139

 

RD#

 

RD#

 

RD132

 

RD132

 

RD117

 

RD123


 

RD140

 

RD141

 

RD142

 

RD145

 

RD146

 

RD92

 

RD92


 

RD147

 

RD148

 

RD149

 

RD150

 

RD151

 

RD152

 

RD153

 

RD154

 

RD92

 

RD92


 

RD155

 

RD156

 

RD157

 

RD158

 

RD159

 

RD160

 

RD161

 

RD162

 

RD147

 

RD147

 

RD154

 

RD#


 

 

RD163

 

RD164

RD#

 

RD#

 

26

 

26

 

RD155

 

RD162